The contractor shall to engineer novel HIV GP41 ectodomain antigens (HIV GP41E-HD) for the incorporation into the immunogenic vesivax formulations.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00012
- Awardee
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · SBIRPHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50014, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small business set-aside award is associated with the larger SBIR program vehicle to develop medical technologies, diagnostics, vaccines and other innovations through contracts ranging from $100,000 to $1.5 million over periods up to 33 months.
Quick answers
Who was awarded contract 75N93022C00012?
75N93022C00012 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.
How much is contract 75N93022C00012 worth?
The government has obligated $300,000 on 75N93022C00012.
Was contract 75N93022C00012 competed?
The extent of competition for 75N93022C00012 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award